Enhancement of PAI-1 mRNA in cardiovascular cells after kainate injection is mediated through the sympathetic nervous system

Journal of Molecular and Cellular Cardiology

Volumn 38, Issue 5, 2005, Pages 715-722

  Miskin, Ruth ^a   Abramovitz, Rene ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Cardiovascular system; Kainate; PAI 1 mRNA; Plasminogen activator inhibitor 1; Sympathetic nervous system; 1 Adrenergic receptor

Indexed keywords

ADRENALIN; ALPHA 1 ADRENERGIC RECEPTOR; ATROPINE; CLONIDINE; GUANETHIDINE; KAINIC ACID; MECAMYLAMINE; MESSENGER RNA; PHENTOLAMINE; PHENYLEPHRINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROPRANOLOL;

ADRENERGIC SYSTEM; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORONARY ARTERY; FEMALE; GENE ACTIVATION; GENE EXPRESSION; HEART MUSCLE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION;

EID: 17844388868     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2005.02.016     Document Type: Article

References (55)

1. D.S. Martin, and J.R. Haywood Sympathetic nervous system activation by glutamate injections into the paraventricular nucleus Brain Res. 577 1992 261 267
2. M.Z. Goren, F. Onat, and K. Berkman Participation of NMDA and kainate receptors of paraventricular nucleus in cardiovascular responses to glutamate receptor agonist Eur. J. Pharmacol. 388 2000 77 84
3. K. Sundaram, and H. Sapru NMDA receptors in the intermediolateral column of the spinal cord mediate sympathoexcitatory cardiac responses elicited from the ventrolateral medullary pressor area Brain Res. 544 1991 33 41
4. B. Venugopal, R. Sharon, R. Abramovitz, A. Khasin, and R. Miskin Plasminogen activator inhibitor-1 in cardiovascular cells: rapid induction after injecting mice with kainate or adrenergic agents Cardiovasc. Res. 49 2001 476 483
5. D.J. Loskutoff Regulation of PAI-1 gene expression Fibrinolysis 5 1991 197 206
6. M. van Meijer, and H. Pannekoek Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update Fibrinolysis 9 1995 263 276
7. H.P. Kohler, and P.J. Grant Plasminogen-activator inhibitor type 1 and coronary artery disease N. Engl. J. Med. 342 2000 1792 1801
8. V.A. Ploplis, P. Carmeliet, S. Vazirzadeh, I. Van Vlaenderen, L. Moons, and E.F. Plow Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice Circulation 92 1995 2585 2593
9. J.D. Vassalli, A.P. Sappino, and D. Belin The plasminogen activator/plasmin system J. Clin. Invest. 88 1991 1067 1072
10. L. Devy, S. Blacher, C. Grignet-Debrus, K. Bajou, V. Masson, and R.D. Gerard The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent FASEB J. 16 2002 147 154
11. E. Creemers, J. Cleutjens, J. Smits, S. Heymans, L. Moons, and D. Collen Distruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction Am. J. Pathol. 156 2000 1865 1873
12. P.A. Andreasen, L. Kjoller, L. Christensen, and M.J. Duffy The urokinase type plasminogen activator system in cancer metastasis: a review Int. J. Cancer 72 1997 1 22
13. Z. Qian, M.E. Gilbert, M.A. Colicos, E.R. Kandel, and D. Kuhl Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation Nature 361 1993 453 457
14. Z.L. Chen, and S. Stickland Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin Cell 91 1997 917 925
15. H.A. Chapman Plaminogen activators, integrins, and the coordinated regulation of cell adhesion and migration Cur Opin Cell Biol 9 1997 714 724
16. P. Carmeliet, and D. Collen Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis FASEB J. 9 1995 934 938
17. A. Luttun, F. Lupu, E. Storkebaum, M.F. Hoylaerts, L. Moons, and J. Crawley Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice Arterioscler. Thromb. Vasc. Biol. 22 2002 499 505
18. S. Heymans, A. Luttun, D. Nuyens, G. Theilmeier, E. Creemers, and L. Moons Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure Nat. Med. 5 1999 1135 1142
19. K. Yamamoto, and H. Saito A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders Int. J. Hematol. 68 1998 371 385
20. B. Wiman, and A. Hamsten The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease Semin. Thromb. Hemost. 16 1990 207 216
21. W. Koenig Haemostatic risk factors for cardiovascular diseases Eur. Heart J. 19 Suppl C 1998 C39 C43
22. M. Cesari, and G.P. Rossi Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy Arterioscler. Thromb. Vasc. Biol. 19 1999 1378 1386
23. A. Festa, R.J. D'Agostino, R.P. Tracy, and S.M. Haffner Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study Diabetes 51 2002 1131 1137
24. K. Yamamoto, K. Takeshita, T. Shimokawa, H. Yi, K.-I. Isobe, and D.J. Loskutoff Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals Proc. Natl. Acad. Sci. USA 99 2002 890 895
25. T. Masos, and R. Miskin mRNAs encoding urokinase-type plasminogen activator and plasminogen activator inhibitor-1 are elevated in the mouse brain following kainate-mediated excitation Brain Res. Mol. Brain Res. 47 1997 157 169
26. G.P. Gasic, and M. Hollmann Molecular neurobiology of glutamate receptors Annu. Rev. Physiol. 54 1992 507 536
27. S.A. Lipton, and P.A. Rosenberg Excitatory amino acids as a final common pathway for neurologic disorders N. Engl. J. Med. 330 1994 613 622
28. J. Lerma Kainate receptors: an interplay between excitatory and inhibitory synapses FEBS Lett. 43 1998 100 104
29. E.M. Johnson, and P.T. Manning Guanethidine-induced destruction of sympathetic neurons Int. Rev. Neurobiol. 25 1984 1 37
30. E.M. Johnson, M.A. Palmatier, R.E. Rydel, and P.T. Manning Species and structural specificity of the lipopigment accumulation and neuronal destruction induced by N-(2-guanidinoethyl)-4-methyl-1,2,5,6-tetrahydropyridine (guanacline) Brain Res. 383 1986 100 109
31. N. Meiri, T. Masos, K. Rosenblum, R. Miskin, and Y. Dudai Overexpression of urokinase-type plasminogen activator in transgenic mice is correlated with impaired learning Proc. Natl. Acad. Sci. USA 91 1994 3196 3200
32. P.T. Larsson, N.H. Wallen, B. Wiman, and G. Dooijewaard α- and β-adrenergic influences on the tissue and urokinase plasminogen activator systems Fibrinol. Proteol. 13 1999 169 175
33. T. Peng, X. Jiang, Y. Wang, A. Hand, C. Gillies, and R.E. Cone Sympathectomy decreases and adrenergic stimulation increases the release of tissue plasminogen activator (t-PA) from blood vessels: functional evidence for a neurologic regulation of plasmin production within vessel walls and other tissue matrices J. Neurosci. Res. 57 1999 680 692
34. L. Hein, and B.K. Kobilka Adrenergic receptor signal transduction and regulation Neuropharmacology 34 1995 357 366
35. Y. Ben-Ari, and R. Cossart Kainate, a double agent that generates seizures: two decades of progress Trends Neurosci. 23 2000 580 587
36. Z.J. Bosnjak, and J.P. Kampine Cardiac sympathetic afferent cell bodies are located in the peripheral nervous system of the cat Circ. Res. 64 1989 554 562
37. M.H. Huang, S.G. Wolf, and J.A. Armour Ventricular arrhythmias induced by chemically modified intrinsic cardiac neurones Cardiovasc. Res. 28 1994 636 642
38. R.W. Mueller, S.S. Gill, and O.M. Pulido The monkey (Macaca fascicularis) heart neural structures and conducting system: an immunochemical study of selected neural biomarkers and glutamate receptors Toxicol. Pathol. 31 2003 227 234
39. S.S. Gill, O.M. Pulido, R.W. Mueller, and P.F. McGuire Molecular and immunochemical chracterization of the ionotropic glutamate receptors in the rat heart Brain Res. Bull. 46 1998 429 434
40. S.S. Gill, and O.M. Pulido Glutamate receptors in peripheral tissues: current knowledge, future research, and implications for toxicology Toxicol. Pathol. 29 2001 208 223
41. P.T. Larsson, B. Wiman, G. Olsson, B. Angelin, and P. Hjemdahl Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis Thromb. Haemost. 63 1990 482 487
42. W.L. Chandler, W.C. Levy, R.C. Veith, and J.R. Stratton A kinetic model of the circulatory regulation of tissue plasminogen activator during exercise, epinephrine infusion, and endurance training Blood 81 1993 3293
43. H. Gottschling-Zeller, I. Aprath, T. Skurk, and H. Hauner Beta-adrenoceptor agonists and other cAMP elevating agents suppress PAI-1 production of human adipocytes in primary culture Horm. Metab. Res. 32 2000 509 514
44. C.M. Halleux, P.J. Declerck, S.L. Tran, R. Detry, and S.M. Brichard Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines J. Clin. Endocrinol. Metab. 84 1999 4097 4105
45. R.N. Doughty, and N. Sharpe Beta-adrenergic blocking agents in the treatment of congestive heart failure: mechanisms and clinical results Annu. Rev. Med. 48 1997 103 114
46. S.R. Post, H.K. Hammond, and P.A. Insel β-Adrenergic receptors and receptor signaling in heart failure Annu. Rev. Pharmacol. Toxicol. 39 1999 343 360
47. O.-E. Brodde, S. Hilemann, K. Kunde, M. Vogelsand, and H.-R. Zerkowski Receptor systems affecting force of contraction in the human heart and their alterations in chronic heart failure J. Heart Lung Transplant. 11 1992 S164 SS74
48. J.J. Hunter, and K.R. Chien Signaling pathways for cardiac hypertrophy and failure N. Engl. J. Med. 341 1999 1276 1283
49. M. Irlbeck, O. Muhling, T. Iwai, and H.-G. Zimmer Different response of the rat left and right heart to norepinephrine Cardiovasc. Res. 31 1996 157 162
50. W. Zierhut, and H.-G. Zimmer Significance of myocardial α- and β-adrenoceptors in catecholamine-induced cardiac hypertrophy Circ. Res. 65 1989 1417 1425
51. P. Simpson Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response J. Clin. Invest. 72 1983 732 738
52. 1B- adrenergic receptor in transgenic mice induces cardiac hypertrophy Proc. Natl. Acad. Sci. USA 91 1994 10109 10113
53. K. Swedberg, C. Viquerat, J.L. Rouleau, M. Roizen, B. Atherton, and W.W. Parmley Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure Am. J. Cardiol. 54 1984 783 786
54. G.J. Hasking, M.D. Esler, G.L. Jennings, D. Burton, J.A. Johns, and P.I. Korner Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity Circulation 73 1986 615 621
55. C.M. Bloor, L. Nimmo, M.D. McKirnan, Y. Zhang, and F.C. White Increased gene expression of plasminogen activators and inhibitors in left ventricular hypertrophy Mol. Cell. Biochem. 176 1997 265 271